Jotair L Tablet contains Levocetirizine 5mg and Montelukast 10mg, combining an antihistamine and a leukotriene receptor antagonist to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, reducing symptoms such as sneezing, rhinorrhea, nasal itching, and ocular irritation associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, thereby preventing bronchoconstriction, inflammation, and mucus production commonly observed in asthma and allergic rhinitis. The combination is indicated for the management of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunctive therapy in asthma to improve symptom control and reduce exacerbations. Jotair L Tablet is typically administered once daily, preferably in the evening, with or without food. It is generally well tolerated; however, patients should be monitored for potential adverse effects such as headache, fatigue, gastrointestinal disturbances, and neuropsychiatric symptoms. Caution is advised in patients with hepatic or renal impairment. Jotair L Tablet offers a synergistic approach by addressing multiple inflammatory pathways involved in allergic disorders, enhancing patient compliance and therapeutic outcomes. Always consult a healthcare professional before initiating therapy.